PsyIndex

The easiest way to track the public and private psychedelics markets and breaking news.

[PsyIndex @ThePsyIndex]

$MXT $MXTTF
@MedXtractor anticipates that SHAMAN and YMI will generate revenue in late 2021. At the same time, the company has been developing these technologies on a tight budget to minimize shareholder dilution and maximize profitability.
https://t.co/2vOnr9kVYB

[PsyIndex @ThePsyIndex]

#CatalystSummit 2022
May 20 – 22, 2022 | Online
Canada’s 3rd annual conference dedicated to #psychedelicmedicine, is a hybrid event that can be attended online or in-person at #QueensUniversity in Kingston, #Ontario.
https://t.co/nVsvmisFd7

[PsyIndex @ThePsyIndex]

$EHVVF @Ehaveinc1's EHR platform provides critical solutions for mental health providers and patients. However, the company’s software business represents just one of its many areas of focus...
https://t.co/zImpScfTCY

[PsyIndex @ThePsyIndex]

$EHVVF @ehaveinc
Patients can instantly connect with highly skilled nurses for ketamine therapy at their home, office or hotel, and an intelligent dashboard will measure treatment efficacy. The service is already available in 50+ major US cities & Canada.
https://t.co/KmiMOjM0T2

[PsyIndex @ThePsyIndex]

$ENVB @Enveric_Bio intends to expand into a next-generation neuroscience drug discovery platform of novel psychedelics that address the large unmet mental health challenges related to CNS indications...
https://t.co/ilfQ7Jq4Hw

[PsyIndex @ThePsyIndex]

$EHVVF
@ehaveinc: pushing forward on a number of fronts, utilizing data + artificial intelligence to improve mental health treatments with effective remote tools—& leading the charge to further define HPPD and develop a standardized test for the condition.
https://t.co/F4RvDy1DKM

[PsyIndex @ThePsyIndex]

$MEDI $KONEF $MYO
@KetamineOne aims to continue to acquire medical clinics across the US and is developing cutting-edge technologies, such as virtual reality and wearables, to enhance and measure psychedelic experiences and improve outcomes.
https://t.co/O3icBFOzru

[PsyIndex @ThePsyIndex]

$SILO
#SiloPharma's notice of allowance paves the way toward clinical trials for its psychedelics delivery platform using homing peptides.
https://t.co/z3LOhQpKt0

[PsyIndex @ThePsyIndex]

$MEDI $KONEF
@KetamineOne has acquired 16 clinics across North America (15 in Canada and one in the United States) with letters of intent to acquire an additional three clinics, making it one of the most mature companies in the space.
https://t.co/69NhYxd3EC

[PsyIndex @ThePsyIndex]

$MEDI $KONEF
@KetamineOne has acquired 16 clinics across North America (15 in Canada and one in the United States) with letters of intent to acquire an additional three clinics, making it one of the most mature companies in the space.
https://t.co/69NhYxd3EC

[PsyIndex @ThePsyIndex]

$MXT $MXTTF
Known for its award-winning extraction equipment, @MedXtractor recently refocused its efforts on its proprietary health-related databases, machine learning analysis, and plans to engage in B2B licensing and mHealth.
https://t.co/1OE67WK2y9

[PsyIndex @ThePsyIndex]

$MXT $MXTTF
Known for its award-winning extraction equipment, @MedXtractor recently refocused its efforts on its proprietary health-related databases, machine learning analysis, and plans to engage in B2B licensing and mHealth.
https://t.co/1OE67WK2y9

[PsyIndex @ThePsyIndex]

$ENVB @EnvericBio
@MagicMedInd
The combined capabilities of the two companies could serve to greatly enhance our understanding of both cannabis and psychedelic science after decades of neglect.
https://t.co/mBVvSHAxo1

[CFN Media @CFNMediaNews]

$ENVB @EnvericBio
@MagicMedInd
The combined capabilities of the two companies could serve to greatly enhance our understanding of both cannabis and #psychedelic science after decades of neglect.
https://t.co/svs0sOGZZS #stocks #investing

[PsyIndex @ThePsyIndex]

$EHVVF
@ehaveinc: taking one of the most innovative approaches through its KetaDASH & wider data-driven strategy to aggregate health data and analyze it with machine learning algorithms to diagnose mental health disorders and evaluate treatment options.
https://t.co/2NsTLl6bt9

[CFN Media @CFNMediaNews]

$MEDI
With plans to become the largest clinic network in North America, @KetamineOne's compelling business plan ventures beyond clinics to build value through wearables, telehealth, & data collection + analysis.
https://t.co/ZJIKPhFbGo

[PsyIndex @ThePsyIndex]

$CNFN @CannabisFN
$ENVB @EnvericBio @MagicMedInd
#Investors looking for regulated + transparent access to these emerging sectors may want to keep an eye on the company as the transaction is finalized and #Enveric embarks on its expanded mission.
https://t.co/W9MaWqjgtq

[PsychedelicStockWatch @PsychStockWatch]

Strong close for #psychedelicstocks with lots of green on display. Both $NUMI (+8.82%) and $CYBN (+10.46%) powered higher for a 2nd straight day on heavy volume.

The other Top-7 #psychedelicstocks:

ATAI +2.26%
CMPS +1.64%
MNMD +3.41%
$FTRP +8.61%
GHRS +4.39%

#shroomstocks

[PsychedelicStockWatch @PsychStockWatch]

Some big gains at the close for other leading #psychedelicstocks. $MYCO (+21.65%) had another huge day on big volume. $NM (+22.68%) also jumped.

MCUR +2.27%
ENBI +5.41%
PSYC even
TRIP +5.26%
DRUG -2.07%
PSYG even
OPTI -3.80%
WESA -3.51%
$DMT +11.11%

#shroomstocks

[CFN Media @CFNMediaNews]

The achievement of an industry milestone providing access to #psilocybin #mushrooms to further their legal research as a treatment for #mentalhealth disorders...
@wake_network
https://t.co/TKNN0pMNR0